No Data
No Data
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
Inozyme Pharma Price Target Maintained With a $23.00/Share by Needham
Inozyme Pharma Price Target Maintained With a $23.00/Share by Needham
Inozyme Pharma Buy Rating Affirmed on Strong Trial Results and Robust Pipeline Prospects
Inozyme Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 400% Needham → $23 Reiterates Buy → Buy 04/10/2024 400% Needham → $23 Reiterates Buy → Buy 04/0
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Inozyme Pharma (INZY)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Esperion (ESPR) and Madrigal Pharmaceuticals (MDGL)
全力買い : バイオおすすめありますか?